• Pacira Biosciences shifted PCRX-201, an investigational gene therapy for knee osteoarthritis, to a U.S.-based commercial-scale manufacturing process.
• Drug supply from the new process enabled first patient enrollment in Part B of the Phase 2 ASCEND study.
• Part A enrollment ended in June; topline results are expected by end of 2026 and have not yet been presented.
• Management framed the manufacturing transition as de-risking later-stage development by generating Phase 2 data with the intended commercial process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.